Atossa Therapeutics (NASDAQ: ATOS) is an early-stage biopharmaceutical that is slowly making progress with a Covid-19-related treatment. ATOS stock has been declining, given that investors have little to latch onto at the present moment.
Bleak Financial Outlook for ATOS
Atossa Therapeutics (ATOS) has not had a good year in the stock market, with ATOS stock price decline of over 75% seen in the last 12 months alone. This lack of confidence by market participants comes as a direct result of poor fundamentals, and little substance to hold on to that would warrant investing one’s capital in. Its EPS of -$0.05 marginally beat the analyst consensus of -$0.06. Moreover, its operating expenses saw a reduction from $7,000 to $6,595 on a year-on-year basis. Its cash holdings have decreased since the prior quarter from $131,100 to $125,500. This clearly points to financing challenges for large-scale drug development.
Atossa Therapeutics Pipeline and Progress
Financials, at this point of the company’s lifecycle, do not reflect the inherent value it holds, which is typical of an early-stage bio-pharmaceutical. The company has initiated a number of procedures in the development process of its AT-H201 drug candidate, after the completion of parts B and C of its phase 1/2a clinical trial. Although this stage of the development process is far too early for an opinion to be formed about the drug’s viability, it is progress nonetheless. To add, Atossa also entered into an agreement with a US venture capital firm that will assist the company in relation to operations, personnel, and intellectual property.
At present, ATOS stock has little substance going for it, the result of which the market does not have a reason to be confident about its prospects. However, progress is slow, which is better than its affairs being at a complete standstill.